ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 485

Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis

Candice Low1, Richard Conway 2, Francis Young 1, Eamonn Molloy 3, Anne Barbara Mongey 3, Gerry Wilson 3, Ursula Fearon 4 and Douglas Veale 5, 1Saint Vincent's University Hospital, Dublin, Ireland, 2Blackrock Clinic, Dublin, Ireland, 3St Vincent's University Hospital, Dublin, Ireland, 4Molecular Rheumatology, Trinity Biomedical Sciences Institute, TCD, Dublin, Ireland, 5EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Early Rheumatoid Arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Seropositive arthralgia is defined as joint pain in patients positive for rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA). It is a precursor to rheumatoid arthritis (RA) in some individuals. Clinical and synovial findings in seropositive arthralgia when compared to RA and osteoarthritis (OA) have not been fully defined. Our aim was to compare clinical characteristics, macroscopic arthroscopy findings, and synovial immunohistochemical findings in those with seropositive arthralgia, RA, and OA.

Methods: We performed a prospective study of consecutive patients with seropositive arthralgia. All patients were seropositive for RF and/or ACPA. Demographic and clinical characteristics were collected on all patients. Synovial biopsy was performed by needle arthroscopy in all patients, and macroscopic and histologic features recorded. The degree of synovitis and vascularity were recorded on a 0–100-mm visual analog scale. We compared the findings in this group to 2 other cohorts; patients with established diagnoses of either RA or OA as per ACR classification criteria. Whitney U test was used to compare groups. GraphPad Prism Version 8 and IBM SPSS Statistics Version 24 were used for data analysis.

Results: 54 patients were recruited, 33 with seropositive arthralgia, 14 with RA, and 7 with OA. Compared to seropositive arthralgia, established RA patients had higher tender and swollen joint counts, CRP and ESR, patient global assessment (PGA) of disease activity, and DAS28-CRP, Table 1. In contrast, the only difference between seropositive arthralgia and OA patients was higher PGA in the OA group, Table 1. RA patients had significantly greater macroscopic synovitis and synovial vascularity than seropositive arthralgia patients who were not significantly different to OA patients, Table 1, Figure 1. On synovial biopsy, synovial lining layer thickness and microscopic vascularity were increased in RA compared to seropositive arthralgia; there was no difference between seropositive arthralgia and OA. On immunohistochemical analysis of synovial tissue, CD3 and CD38 but not CD138 expression were higher in RA compared to seropositive arthralgia, Figure 2. CD3 and CD38 but not CD138 expression, were higher in seropositive arthralgia compared to OA, Figure 2.

Conclusion: Baseline clinical characteristics, macroscopic arthroscopic findings, and microscopic histologic findings in seropositive arthralgia are more similar to OA than established RA patients. However, key differences in synovial inflammatory cell populations are identifiable in seropositive arthralgia on immunohistochemical analysis.

Table 1: Characteristics of patients with seropositive arthralgia, RA, and OA

Figure 1: Macroscopic synovitis and vascularity in seropositive arthralgia, RA, and OA.

Figure 2: Comparison of synovial biopsy and immunohistochemical findings in seropositive arthralgia, RA, and OA.


Disclosure: C. Low, None; R. Conway, None; F. Young, None; E. Molloy, None; A. Mongey, None; G. Wilson, None; U. Fearon, None; D. Veale, Health Beacon, 1.

To cite this abstract in AMA style:

Low C, Conway R, Young F, Molloy E, Mongey A, Wilson G, Fearon U, Veale D. Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/comparison-of-clinical-features-synovial-histology-and-immunohistochemistry-in-seropositive-arthralgia-rheumatoid-arthritis-and-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-clinical-features-synovial-histology-and-immunohistochemistry-in-seropositive-arthralgia-rheumatoid-arthritis-and-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology